Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + SHR6390 + letrozole neoadjuvant trial in stage II-III triple-positive breast cancer
ChiCTR2000034827Phase 3Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pyrotinib, dalpiciclib and letrozole in breast cancer, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Total pathological complete response. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
pyrotinibdalpiciclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000034827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034827.